entertainment -WSS

entertainment

author：knowledge 2025-09-28 00:48:59 - browse：9579

A judge ruled that Welsh Carson won't have to face antitrust allegations about its anesthesiology practice. Adobe

Welsh, Carson, Anderson & Stowe has wiggled out of the grasp of the Federal Trade Commission, but the private equity firm’s anesthesia company, U.S. Anesthesia Partners, still must face the agency’s antitrust case, a judge ruled last week.

The FTC alleged last year that the anesthesiology network monopolized markets in Texas to drive up prices, but took the unusual step of attaching Welsh Carson as a defendant with USAP. Dismissing Welsh Carson from the case was a victory for the private equity firm and, more broadly, other firms worried that the Biden administration would try to hold them responsible for anything their portfolio companies do.

But the allegations against USAP didn’t disappear, which will keep up scrutiny on companies that have made a push to acquire numerous physician groups.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Novo: Oral version of Ozempic leads to 15% weight loss

WSS

Military medical care influenced by rank and race, new study finds

Eli Lilly’s Mounjaro succeeds in second weight

Big Tobacco's 'harm reduction': Is it for real, or a sham?

The thinking behind the controversial eating disorder chatbot Tessa

When prostate cancer spreads, where it goes matters

Reanimated hearts work just as well for transplants, study finds

explore

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

focus

What does generative AI mean for health care? We asked experts

Addiction experts warn against a second 'war on drugs'

Novavax promises a turnaround & Lilly roils the obesity market

Data integrity in scientific journals requires "effort" by publishers, institutions

Continuity nursing helped my family in our darkest PICU moments

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Jerome Adams on the need for new antivirals for Covid

When prostate cancer spreads, where it goes matters

Jerome Adams on the need for new antivirals for Covid

When prostate cancer spreads, where it goes matters

focus

Reanimated hearts work just as well for transplants, study finds

Novo pauses ads for weight loss drug Wegovy amid demand

FDA approves first new drug developed for postpartum depression

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Biogen nominates mother of director’s child to replace him on board

entertainment

hotspot

explore

focus